Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 1447818

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 1447818

Global mRNA Therapeutics Market Size, Share, Growth Analysis, By Type(Prophylactic Vaccines, Therapeutic Vaccines), By Application(Rare Genetic Diseases, Oncology) - Industry Forecast 2024-2031

PUBLISHED:
PAGES: 157 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5300
PDF & Excel (Multiple User License)
USD 6200
PDF & Excel (Enterprise License)
USD 7100

Add to Cart

Global MRNA Therapeutics Market size was valued at USD 40.80 Billion in 2022 and is poised to grow from USD 41.62 Billion in 2023 to USD 48.76 Billion by 2031, at a CAGR of 2% during the forecast period (2024-2031).

mRNA-based therapeutics have recently gained significant attention as a promising solution for effectively treating chronic conditions, leading to the steady and assured growth of the market. In recent times, mRNA vaccines have become preferred over DNA vaccines due to their advantages in production and distribution, offering a safer alternative. These vaccines and therapeutics have successfully undergone human clinical trials, further boosting demand for these products. Companies like Moderna and Pfizer-BioNTech have played a major role in the market, particularly during the COVID-19 pandemic. Their vaccines developed in response to the global health crisis significantly fueled market growth. mRNA therapeutics are also prominently used in oncology clinical trials, with mRNA vaccine trials for cancer patients in 2021 attracting a substantial number of volunteers, ranking second highest in participation, excluding COVID-19 trials in cancer patients. The industry has witnessed remarkable growth since then. The emergence of new variants of the SARS-CoV-2 virus worldwide has emphasized the need for effective vaccines, prompting medical professionals to turn to mRNA vaccines. The COVID-19 pandemic accelerated the utilization of mRNA-based products, further driving market expansion. Messenger RNA has emerged as a powerful therapeutic tool, thanks to technological advancements that improve translation and stability, as well as delivery techniques. The pharmaceutical industry recognizes the potential for expansion through mRNA vaccines, indicating promising growth prospects for the market. mRNA vaccines represent the next stage in vaccine development, ushering in a new era in immunization. An excellent example of this is the collaboration between Moderna Inc. and the National Institute of Allergy and Infectious Diseases, which resulted in the creation of mRNA-1273 (NIAID) in March 2020. This vaccine demonstrated a 94.1% efficacy rate in preventing symptomatic COVID-19, receiving expedited approval from the US FDA and emergency use authorization in December 2020. Furthermore, the rapidly expanding field of mRNA therapeutics is set to revolutionize personalized medicine, transforming traditional healthcare standards and increasing the demand for mRNA-based products in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global MRNA Therapeutics and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global MRNA Therapeutics Market Segmental Analysis

The global mRNA therapeutics market is segmented on the basis of type, application, region. By type, the market is segmented into prophylactic vaccines, therapeutic vaccines, therapeutic drugs. By application, the market is segmented into rare genetic diseases, oncology, respiratory diseases, infectious diseases, others. By end-use, the market is segmented into hospitals & clinics, research organizations, others. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.

Drivers of the Global MRNA Therapeutics Market

The COVID-19 pandemic accelerated the development of mRNA vaccines, highlighting mRNA technology's effectiveness in fighting infectious diseases.

Growing investments from public and private sectors, such as government agencies and venture capital firms, are fuelling research and development (R&D) activities in mRNA therapies.

An increase in clinical trials for a range of illnesses, including cancer, rare genetic disorders, and infectious diseases, is driving the market's growth.

Restraints in the Global MRNA Therapeutics Market

The global market for mRNA therapeutics encountered several challenges, particularly in the production and distribution processes. Scaling up mRNA production capacity while maintaining a stable supply chain was notably challenging, especially during a global health crisis.

There are inherent risks in mRNA therapeutics, requiring extensive testing, experimentation, and analysis. Concerns arise regarding potential immune responses or off-target effects, which could pose safety risks in the future and potentially impede market growth.

The mRNA therapeutics market faces competition from emerging technologies and established treatments that offer similar benefits without the potential safety concerns. These alternative therapies pose a threat to the growth of the mRNA therapeutics market.

Market Trends of the Global MRNA Therapeutics Market

mRNA Cancer Vaccines: The market for mRNA cancer vaccines is experiencing a notable and impactful trend. The development of cancer vaccines using mRNA technology presents a significant opportunity for advancements in oncology treatment and therapy.

Partnerships and Collaborations: Another prevailing trend in the market and related industries is the increasing focus on mRNA product development and the rise in expertise within the field. This is largely due to the growing number of collaborations and mergers among global pharmaceutical companies.

Orphan Diseases: The market has also witnessed the emergence of a significant trend involving the treatment of rare diseases. The therapeutics offered by this market have the potential to address medical needs that have previously gone untreated, particularly in the realm of orphan diseases. As a result, mRNA therapies are gaining increased attention from medical professionals and patients alike.

Product Code: SQMIG35A2547

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global mRNA Therapeutics Market by Type

  • Market Overview
  • Prophylactic Vaccines
  • Therapeutic Vaccines
  • Therapeutic Drugs

Global mRNA Therapeutics Market by Application

  • Market Overview
  • Rare Genetic Diseases
  • Oncology
  • Respiratory Diseases
  • Infectious Diseases
  • Others

Global mRNA Therapeutics Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • CureVac AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche Holding AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Moderna, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi SA (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioNTech SE (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dynavax Technologies Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Arcturus Therapeutics Holdings Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca plc (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Regeneron Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Alnylam Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Modulus Therapeutics, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Catalent, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Translate Bio, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ionis Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vertex Pharmaceuticals Incorporated (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!